Open label trial of adjuvant immunotherapy with Dzherelo, Svitanok, and Lizorm, in MDR-TB, XDR-TB and TB/HIV co-infected patients receiving anti-tuberculosis therapy under DOT
Nathalia D. Prihoda1, Olga V. Arjanova1, Lyudmila V. Yurchenko1, Nina I. Sokolenko1, Lyudmila A. Vihrova2, Volodymyr S. Pylypchuk3, Galyna A. Kutsyna4*
1Lisichansk Tuberculosis Dispensary, Lisichansk, Ukraine.
2Lisichansk Regional Hospital, Lisichansk, Ukraine.
3Ekomed LLC, Kiev, Ukraine.
4Luhansk Regional AIDS Center and Luhansk State Medical University, Luhansk, Ukraine.
Email: [email protected]